Remdesivir (GS-5734)

Catalog No.S8932

For research use only.

Remdesivir (GS-5734), a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.

Remdesivir (GS-5734) Chemical Structure

CAS No. 1809249-37-3

Selleck's Remdesivir (GS-5734) has been cited by 61 publications

Purity & Quality Control

Choose Selective Antiviral Inhibitors

Biological Activity

Description Remdesivir (GS-5734), a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.
In vitro

GS-5734 exhibits antiviral activity against multiple variants of EBOV in cell-based assays(EC50=0.06-0.14 μM) and broad-spectrum antiviral activity in vitro against other pathogenic RNA viruses. [1]GS-5734 acts as a broad-spectrum therapeutic to protect against CoVs with EC50 of 0.03 μM for murine hepatitis virus in delayed brain tumor cells and 0.074 μM for SARS-CoV and MERS-CoV in HAE cells.[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep2 M1\rWmFvfGm4aYLhcEBi[3Srdnn0fUBie3OjeR?= MlrUOEBl[Xm| NWjXWmNkTUN3MDC9JFAvODF3IN88US=> M2HRelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUK0PVA4Lz5{OEGyOFkxPzxxYU6=
TERT-immortalized HMVEC NXnqSGJQSW62aY\pdoFtKGGldHn2bZR6KGG|c3H5 MY[zJJRwKDRiZHH5dy=> MVXFR|UxKD1iMD6wOVMh|ryP NUjlUJlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNlQ6ODdpPkK4NVI1QTB5PD;hQi=>
HuH7 M2\TbGFvfGm4aYLhcEBi[3Srdnn0fUBie3OjeR?= NGHT[ZE{KGSjeYO= M{fJcmVEPTBiPTCwMlA2PyEQvF2= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF{NEmwO{c,OjhzMkS5NFc9N2F-
HuH7 M1HLUGFvfGm4aYLhcEBi[3Srdnn0fUBie3OjeR?= MmHlN{Bl[Xm| MkHXSWM2OCB;IECuNFch|ryP MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OUK3OlMoRjJ6N{myO|Y{RC:jPh?=
macrophages MnfORY51cX[rcnHsJIFkfGm4aYT5JIF{e2G7 M1jWdlQ5KGh? NGPkVY5GSzVyIE2gNE4xQDZizszN MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF{NEmwO{c,OjhzMkS5NFc9N2F-
macrophages M{\zUGFvfGm4aYLhcEBi[3Srdnn0fUBie3OjeR?= NHj2NI41QCCq M3LMPGVEPTBiPTCwMlA5PiEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd7Mke2N{c,Ojh5OUK3OlM9N2F-
HeLa MYLBcpRqfmm{YXygZYN1cX[rdImgZZN{[Xl? M1fhSVQ5KGh? M3KwS2VEPTBiPTCwMlEh|ryP NXrVVHJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNlQ6ODdpPkK4NVI1QTB5PD;hQi=>
HeLa NIr4T3lCdnSrdnnyZYwh[WO2aY\peJkh[XO|YYm= NV;JVIZGPDhiaB?= MkjDSWM2OCB;IECuNVQh|ryP NFfWZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe5Nlc3Oyd-Mki3PVI4PjN:L3G+
MT4 NI\PW5pEgXSxdH;4bYNqfHliYYPzZZk> MoDrOEB1dyB3IHThfZM> M2LDcGNEPTBiPTCxMlch|ryP NV\XZoJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNlQ6ODdpPkK4NVI1QTB5PD;hQi=>
Hep2 NWjBcI05S3m2b4TvfIlkcXS7IHHzd4F6 Mn;OOEB1dyB3IHThfZM> MmPxR2M2OCB;IE[uNUDPxE1? M2KzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUK0PVA4Lz5{OEGyOFkxPzxxYU6=
HuH7 M{XERWN6fG:2b4jpZ4l1gSCjc4PhfS=> MWizJIRigXN? M2riWmNEPTBiPTCzOkDPxE1? NXzvXZhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNlQ6ODdpPkK4NVI1QTB5PD;hQi=>
Methods Test Index PMID
Western blot delayed chain termination of RNA synthesis ; tGFP-BlaR / Actin ; ACE2 / Actin ; VP0 / VP2 30987343 33835389 32793908 32595613
Growth inhibition assay Cell viability ; Cell viability ; Cell viability 33835389 33186749 32595613
Pharmacokinetics plasma concentration ; plasma concentration 32589775 33782830
Immunofluorescence MERS-CoV S Protein ; viral S protein and E-caherin ; SARS-CoV-2 / E‐cadherin / VE‐cadherin ; SARS-CoV-2 ; viral dsRNA replication intermediates 33376043 33186749 33173719 32869028 32595613
Viral loads and virus titers SARS-CoV-2 32516797
In vivo

Regardless of the time of initiation, GS-5734 treatment confers improved survival when administered by 3 mg/kg GS-5734. All animals in which 10 mg/kg GS-5734 treatments is initiated 3 days after virus exposure survive to the end of the in-life phase. However, the antiviral effects are consistently greater in animals administered repeated 10 mg/kg GS-5734 doses. The 10 mg/kg D3 (administered beginning 3 days after virus exposure) GS-5734 regimen is associated with amelioration of EVD-related clinical disease signs and markers of coagulopathy and end organ pathophysiology.[1]

Protocol (from reference)

Animal Research:


  • Animal Models: Rhesus monkeys (Macaca mulatta)
  • Dosages: 3 mg / kg, 10 mg / kg
  • Administration: IV

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 602.58


CAS No. 1809249-37-3
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02818582 Completed Drug: GS-5734|Other: Placebo Comparator Ebola National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) July 1 2016 Phase 2

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Remdesivir (GS-5734) | Remdesivir (GS-5734) supplier | purchase Remdesivir (GS-5734) | Remdesivir (GS-5734) cost | Remdesivir (GS-5734) manufacturer | order Remdesivir (GS-5734) | Remdesivir (GS-5734) distributor